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ABSTRACT 
Continuous Pharmaceutical Manufacturing (CPM) has recently emerged as a promising alternative to 
current batch production methods which are plagued by issues of product quality, process reliability 
and cost.  With advances in new continuous synthesis routes, demonstrations of full end-to-end 
continuous drug production and comparative analyses explicitly showing its advantages, CPM has 
been attracting interest at the highest levels of industry and regulators. While continuous chemistry 
has been demonstrated for a variety of Active Pharmaceutical Ingredients (APIs), and there have been 
a few some landmark studies demonstrating practical CPM covering a full design from raw materials 
to final product formulation, fully continuous separation, critical to maximising full CPM potential, 
remains to be fully elucidated. 
In this work we formulate a nonlinear optimisation problem for the CPM of ibuprofen. Adapting 
published continuous synthesis routes and experimental data, and considering reactor design, explicit 
mass transfer, thermodynamics via UNIFAC-estimated API solubilities, and cost estimation, optimal 
total costs were determined for two solvents, toluene and n-hexane, for three different temperature 
cases, 25 °C, 45 °C, and 65 °C. 
A lowest total cost (728.5×103 GBP) is achieved for n-hexane use at 65 °C. The best total cost for 
toluene is only marginally higher (761.4×103 GBP, also at 65 °C). With respect to the E-factor, a 
measure of design sustainability, the cases are comparable: the best E-factor (39.9) is for the n-hexane 
at 65 °C, and the best E-factor for toluene is again close at 42.1 (for 65 °C). Given that the differences 
are small, the use of toluene at 65 °C is the preferable option, as it is more benign than n-hexane. 
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1 INTRODUCTION 
Financial, technical and market pressures on the pharmaceutical industry (Figure 1) have led to the 
emergence of Continuous Pharmaceutical Manufacturing (CPM) as a promising alternative to current 
batch production methods.1 While batch process have advantages including equipment flexibility and 
the ability to recall specific batches, they nevertheless have issues with product quality, process 
reliability and cost;2 as a mature technology, batch process improvements are also incremental at best. 
With advances in new continuous synthesis routes, demonstrations of full end-to-end continuous drug 
production and comparative analyses explicitly showing its advantages, CPM has attracted interest at 
the highest levels of industry and regulators.3,4 
The foundation of any CPM process is the continuous chemistry, and this was demonstrated for a 
variety of APIs from common painkillers to blockbuster anti-cancer medications, as well as key 
substances in the fight against debilitating tropical diseases.6–8 Toward demonstrating practical CPM, 
some landmark studies cover a full design from raw materials to final product formulation.9 However, 
fully continuous separation, critical to maximising full CPM potential, remains to be fully elucidated; 
significant research is being conducted in this field.10 
Process modelling, simulation and cost estimation are rapid and low-cost methodologies for 
evaluating the benefits of continuous processing for the production of pharmaceuticals,1,11–12 while 
optimisation, also called mathematical programming, is a vibrant field with many applications.13–15 It 
has been applied to many aspects of pharmaceuticals and CPM.  
A typical example by Grom et al.16 investigated the reaction kinetics, pathways and process 
optimisation of Lorcaserin, a weight-loss drug belonging to the benzazepine class of heterocyclic 
compounds. The complex kinetics, with over 15 species, 27 reactions, and 29 parameters to be 
optimised, were formulated into a nonlinear regression problem using the Levenberg-Marquadt 
algorithm. The efficient formulation allowed a global optimum to be reached while significantly 
reducing the number of initial approximations required. The model developed allowed the optimal 
process conditions (temperature, reaction time, concentrations) to be found. 
Optimal reactor and process design for the small-scale implementation of continuous ibuprofen 
synthesis – the chemistry for which was developed by Bogdan et al.6 – was studied by Patel et al.17. 
This work focused purely on the specific design and operation of a microreactor (mass and energy 
balances, reaction rates, reactor configuration, the partial differential equations of which were 
discretised) without considering product separation or process economics. The optimisation problem, 
which included 67 degrees of freedom, was formulated as a minimisation of the difference between 
heat removed from and heat generated by the microreactor assembly in order to achieve optimal 
A B 
  
Figure 1. Economic and market pressures faced by the pharmaceutical industry. A: typical R&D sector 
expenditure.5 B: industry sector R&D costs as a percentage of net sales.5 
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configuration and operating conditions; constraints and bounds included residence times, temperature, 
and concentrations.  The results underlie the utility of such investigations of reactor and process 
design toward informing robust and sustainable process options. 
CPM process life-cycle assessments are also excellent candidates for optimisation. By 
systematically considering a diverse set of sustainability metrics such as Process Mass Intensity, 
Cumulative Energy Demand and E-factor in addition to technical parameters. Ott and co-workers18,19 
showed how several routes for rufinamide (an anti-convulsant) synthesis can be compared in a 
meaningful way, elucidating their comparative impacts on the environment, and reducing the LCIA 
(Life Cycle Impact Assessments, another environmental impact metric) by up to 45 %. 
There is also vibrant research investigating the optimisation and control of continuous separation 
and downstream product formulation processes.20-23 Boukouvala and Ierapetritou used surrogate-based 
optimisation to reduce the computational cost of complex solid-based flowsheet models, using 
deterministic Kriging and with added noise;20 the process model used in this case was also used for 
simulations.11,24 The work combines well known simulation-optimization concepts with black-box 
feasibility analyses and heteroscedastic data regression, toward the optimization of computationally 
expensive process.  While the authors acknowledged that the approach does not encapsulate all 
possible sources of variability, it offered good potential for refinement and further development, and 
the added benefit of such approaches will be higher for process of greater inherent complexity.20 In 
contrast to the surrogate approach, others have explicitly optimized an integrated downstream 
 
Figure 2. Demonstrated process flowsheets for ibuprofen CPM.6 
 
Figure 3. Reaction sequence used by Bogdan et al.6 for continuous ibuprofen synthesis.6 
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flowsheet comprising crystallisation, filtration, drying and mixing;21 for the latter there is the 
noteworthy joint use of reduced-order models for particle velocity prediction coupled with population 
balance models for macroscopic property quantification. Separate objective functions for each unit 
operation, optimizing respective aspects of design or operation (e.g. maximizing crystal growth, 
maximizing filtration rate, minimization in deviation from expected final API content specification) 
employed, with robust results; a built-in solver of gPROMS was used, which follows a sequential 
quadratic programming algorithm.21 Abejón et al.22 investigated the optimization of a complex 
nanofiltration cascade, with the objective of minimizing the total cost.  They considered process 
modelling, unit configuration and economic evaluation. The resulting nonlinear optimization problem 
was solved using the GAMS software package, via the use of Pareto diagrams to help identify ideal 
scenarios, and with the additional inclusion of solvent recovery operations, it was found that total 
costs could be reduced by up to 77%. 
In this present work, we present the optimisation of a conceptual upstream flowsheet with product 
Active Pharmaceutical Ingredient (API) recovery: a nonlinear optimisation model is formulated to 
maximise the design Net Present Value/NPV. An explicit model of the entire flowsheet using 
deterministic optimisation, the cost function firstly depends on the economic considerations of 
revenue, operating expenditure (OpEx), and fixed capital expenditure (CapEx), as well as design 
lifetime and rate of inflation. Revenue is determined by the rate of product API recovery from final 
separation. This in turn is determined by technical aspects of the flowsheet, the primary components 
of which are three continuous plug flow reactors with subsequent separation and product recovery. 
The flowsheet is an expanded, more detailed design of previous efforts.25 
 
Figure 4. Continuous ibuprofen synthesis mass balance at key flowsheet points [25]. 
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We also investigate continuous separation schemes to replace a 15-step batch process for final 
product recovery. A range of possible options for continuous separation are included in the model via 
equations governing product recovery and separation: this includes UNIFAC estimation of API 
solubility in a selection of possible ‘green’ solvents (those of lowest toxicity and environmental 
impact, including ethanol, ethyl acetate and acetonitrile) and process operating parameters (e.g. 
temperature, solvent ratio). This is followed by the minimization of total cost by nonlinear 
optimisation on the basis of a detailed continuous process model, where constraints include product 
purity and sustainability (via waste limitation) in addition to technical considerations, before 
concluding some key remarks for optimal CPM process design. 
The scope of this paper builds upon the success of several (academic but also corporate) studies6-10 
which consider continuous flow syntheses and demonstrate original CPM plant implementations; the 
production-scale technical efficiency25,28 and economic viability29,36 of the latter remain to be 
analysed, but it is also critical to hereby evaluate relative CPM solvent performance. The frequent 
scarcity of public-domain kinetics is exacerbated by the dire need for mass transfer efficiency data; if 
this is not essential in batch pharma operations (where equilibrium assumptions may be plausible), it 
is a fundamental necessity in continuous manufacturing, where mass transfer is of critical importance. 
We thus explicitly consider thermodynamics as well as mass transfer efficiency in LLE design, in 
order to perform economic NLP optimisation under a realistic, suitably detailed CPM process model. 
 
2 PROCESS FLOWSHEET AND CONTINUOUS PRODUCT SEPARATION 
Ibuprofen is a widely used, essential painkiller with significant market presence. The first widely 
implemented industrial synthesis method has generally been replaced by a more efficient and simpler 
route. The group of [6] recently synthesised ibuprofen using novel continuous chemistry in a 
landmark study (Figure 2, Figure 3). We have previously performed initial technoeconomic 
evaluations of ibuprofen – using the work of Bogdan et al.6 as a foundation – and also for a key 
antimalarial API.25,28 This work here is an extension of our efforts with regards to ibuprofen. 
 PFR 1 PFR 2 PFR 3 
Reaction 1 2 3 
Reaction order  2 2 2 
Reaction type Friedel-Crafts acylation 1,2-aryl migration Base hydrolysis 
Rate law COOHHCIBBIBB CCkr 521  2)(222 OAcPhICCkr   33 Ckr   
Reactor temperature (°C) 150 50 65 
Conversion (%) 91 98 99 
Rate constant ki  
(L mol−1 hr−1) 31.41 2732.3 15.57 
Coefficient of  
determination (R2) 0.836 0.978 – 
Method for ki Data analysis Data analysis SPARC model26,27 
 
Figure 5. Kinetic data analysis for reactor design.6,25 
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2.1 Reaction scheme 
The ibuprofen process flowsheet studied in this work is based on the publication of Bogdan et al.6 
(Figure 2). Three plug flow rectors (PFRs) in sequence are employed, because of the high yield which 
is achieved in many similar continuous flow synthesis routes, as documented in recent studies4, 6-10; an 
example mass balance (for the same process at a different scale) is given in Figure 4. The equations 
governing the chemical reactions in each reactor are formulated with reaction order and rate constants 
determined from kinetic data analysis of the publication by Bogdan et al.6. In the first PFR, operating 
at 150 °C, the key ingredient isobutyl benzene (IBB) reacts with propanoic acid in a Friedel-Crafts 
acylation reaction, where the solvent is neat triflic acid (TfOH), which also acts as an acid catalyst. A 
conversion of 91% is achieved, producing the intermediate molecule 2, 1-(4-isobutylphenyl)propan-1-
one; the reactor effluent is then chilled to 0°C and mixed with additional reagents and solvents that 
have also been chilled, before progressing to the next PFR.6 
In the second reactor (operating at 50°C) a diacetoxyiodobenzene-mediated 1,2-aryl migration 
reaction transforms intermediate 2 to 2-(4-isobutylphenyl)propanoate, or intermediate 3, at 98% 
conversion. The reactor effluent is combined with a binary water-methanol stream containing 
potassium hydroxide – neutralising the acid – and the resulting mixture enters the third and final 
reactor. 
The saponification of 3 occurs in the third reactor, which operates at 65°C, producing ibuprofen in 
the potassium salt form. This is re-acidified with strong acid – reverting ibuprofen to a carboxylic acid 
– during product purification and recovery.6 
2.2 Continuous API product separation 
Continuous separation alternatives have significant promise in delivering cost and sustainability 
benefits, and here we model two continuous liquid-liquid extraction options we have previously 
reported, using updated modelling tools.25,27,28 The first option uses toluene as a waste-extracting 
solvent, while the second uses n-hexane. The former has the advantages of lower environmental 
impact (toluene is less toxic and damaging than n-hexane), while n-hexane can offer better 
performance in terms of product recovery. Toluene use is normally recommended here; nevertheless, 
n-hexane use is analysed in order to determine the difference in costs. An example flowsheet of this 
separation process is given in Figure 6. After base neutralisation with acid, the resulting acidified 
stream then proceeds to a liquid-liquid extraction operation, where either toluene or n-hexane is used. 
Our essential focus here is designing a continuous liquid-liquid extraction (LLE) vessel, modelled 
as a small mixer-settler, where the mixer is a continuous stirred tank. The reason a continuously 
stirred separation tank (similar to a CSTR) is considered here is the potential to ensure (but also 
manipulate the stirring power toward) a high interfacial area between the aqueous and organic phases, 
which in turn greatly facilitates rapid API mass transfer (continuous plug flow separators have also 
Figure 6. Ibuprofen product recovery: conceptual continuous purification scheme. 
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been demonstrated in the literature, but without control of the interfacial area available for mass 
transfer).40 We consider two distinct liquid-liquid extraction (LLE) solvents (toluene and n-hexane) 
and three distinct temperatures of ambient (25 °C), and intermediate temperature (45 °C) or the 
temperature which coincides with the effluent of the third PFR (65 °C); we employ the UNIFAC 
solubility estimation for computing ibuprofen solubilities. 
Initial investigations of API solubility in a ternary mixture of methanol (the process solvent), water 
(present in significant quantities) and the separation solvent (toluene or n-hexane) illustrate varying 
performance with temperature and rate of separation solvent use. This is illustrated in Figure 7 
(toluene) and Figure 8 (n-hexane), which shows the percentage of API in either the organic or 
aqueous phases that result from the ternary mixture. 
3 NONLINEAR OPTIMISATION PROBLEM 
The formal posing and mathematical formulation of the total cost minimisation considers a sum of 
capital as well as time-discounted operating expenditure. The cost was calculated as the sum required 
to purchase, build and run a given design for a specified time period: 
 
  







1 1
min
t
ty
OpExCapExNPV  (1)
s.t. 
wccont CCBLICCapEx   (2)
wasutlmat CCCOpEx   (3)
 
where the total cost is represented by the Net Present Value, and τ is the design lifetime (20 years), 
and y is the discount rate to the present day (5 %); these are conservative estimates of the economic 
climate and plant longevity, and similar values have been used in previous publications.1, 29, 36 CapEx 
is the capital expenditure (consisting of the Battery-Limits Installed Cost, BLIC, cost of contingency 
Ccont, and working capital, CWC) and OpEx is the operating expenditure (consisting of the cost of 
material purchase, Cmat, utilities (Cutil) and waste disposal, Cwaste). 
Further equations involved in the computing the terms in equations (2-(3) are detailed below. 
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Figure 7. Theoretical API distribution between product aqueous (W) and waste organic (O) phases as a function 
of the solvent-to-feed mass ratio (r), using toluene as the LLE solvent. 
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3.1 Process modelling 
The three plug flow reactors have been simulated using the standard performance equation for a 
second-order reactions: 
 
    mifX0i miXmj0Cmj0CmiXmi0Cmi0C midXk mi0CmQPFRmV   (4)
 
where VPFRm is the volume of reactor m, mQ  is the volumetric flowrate through m, subscripts i and j 
respectively denote reactant species i and j (species i being the one for which reaction data was 
available), ki is the reaction rate constant, and X is conversion. 
For the three reactions that occur here, one in each reactor, rate constant values have been 
determined from systematic evaluation of published kinetic data, while for the last reaction a 
predictive model was used (Figure 5). It should be noted that we are not optimising over the operating 
temperature of the three respective reactors, as we do not have the requisite data to derive explicit 
Arrhenius kinetics. Further details can be found in the publication by.25 The values used are reliable, 
and correspond to the operating temperatures of the reactions. Computed reactor volumes are used to 
estimate their cost. 
To avoid overcomplicating the model (including avoiding explicit UNIFAC equations in the model, 
which could significantly increase computational demand) we have pre-processed and obtained a set 
of data from extensive simulations on the basis of UNIFAC method and derived surrogate equations;31 
the average R2 value for surrogate equations used in this work is over 0.99. 
These have been fitted with either geometric or polynomial functions in order and incorporated into 
the NLP model that we have solved. 
The liquid-liquid-extractor (LLE) was modelled as a mixer-settler. To compute the ternary mole 
fractions of the two liquid phases (organic and aqueous) in the mixer, surrogate equations were used 
(Figure 9): 
 
ipsTipsTipsTipsT CrBrAx  2  (5)
 
where x is mole fraction; subscript p refers to phase (organic or aqueous), s refers to solvent used 
(toluene or n-hexane), and T is temperature (25°C, 45 °C, or 65°C); A, B and C are coefficients; and r 
is the ratio of solvent s to incoming feed stream (by mass). 
The theoretical maximum API recovery is also computed from high-fidelity surrogate equations 
(Figure 10): 
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Figure 8. Theoretical API distribution between product aqueous (W) and waste organic (O) phases as a function 
of the solvent-to-feed mass ratio (r), using n-hexane as the LLE solvent. 
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rsTBsTsTmax eAR
,  (6)
 
To calculate the concentration of ibuprofen in the product stream exiting the mixer, the stage 
efficiency was computed: 
 
1
1




tsTsTsT
sT
sT
VaK
Q
E   (7)
 
where sQ is the volumetric flow through the LLE tank, K is the overall mass-transfer coefficient, a is 
the interfacial area, and Vt is LLE tank volume; other subscripts are as previously described. The rate 
of API recovery is then calculated as follows; 
  sTdsTdstsTsT CCaKf  *  (8)
 
where, *sTdC  is the equilibrium API concentration in the dispersed phase in the mixer, calculated using 
the maximum theoretical API recovery Rmax, while sTdC  is the operating concentration (also that of 
the product stream), which is calculated using the stage efficiency Es,T. 
10 
In order to compute the overall mass-transfer coefficient K, dispersed (subscript d) and continuous 
(subscript c) phase mass-transfer coefficients were computed using the correlation developed by 
Skelland and Moeti:32 
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Figure 9. Determination of surrogate mole fraction equations for water (xH2O), methanol (xMeOH) and LLE 
solvent (xS) ternary phase (organic, O, or aqueous, W) varying by solvent-to-feed ratio r. Surrogate equations 
are fitted second-order polynomials with R2 > 0.96. 
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where Sh are Sherwood numbers, kd and kc the phase-specific mass transfer coefficients, d32 is the 
Sauter mean droplet diameter of the dispersed phase, DAPI is the diffusivity of ibuprofen in the phases, 
Sc is the Schmidt number, Fr the Froude number, Eo the Eotvos number, φ the dispersed phase 
volume fraction, Rei the impeller Reynolds number, di the impeller diameter and dt the tank internal 
diameter: 
 
cAPIc
c
c D
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,
  (12)
g
NdFr iic
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
 gdEo d
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32  (14)
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mii
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where μ is viscosity; ρ is density; σ is surface tension; Ni is impeller rotation speed; g is gravity; Vd 
and Ad are dispersed phase droplet volume and area, respectively; and rAPI is the molecular radius of 
ibuprofen. As before, subscripts c and d refer to the continuous and dispersed phases, while subscript 
p can be either. The Sauter mean droplet diameter, d32, is calculated from the Weber number (We), 
depending on the magnitude of the latter, and there is a maximum permissible size for d32 (10-3 m): 
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Figure 10. Surrogate equations maximum theoretical product recovery (Rmax,sT) in the LLE aqueous (W) phase,
varying by solvent-to-feed ratio r. Surrogate equations are fitted exponential functions with R2 > 0.96. 
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The specific interfacial area a is computed form the dispersed phase volume fraction and the Sauter 
mean droplet diameter: 
 
32
6
d
a   (19)
 
The LLE tank itself was assumed to have a height : diameter ratio of 1, a tank : impeller ratio of 2, 
and an impeller rotation speed of 6 rps. 
3.2 Cost estimation 
The calculations assume that the design will be constructed onsite at an existing pharmaceutical 
facility; a 335-day working year (8,040 hours) was assumed. A variety of vendor data and established 
economic prediction methods were used to estimate both Capital Expenditure (CapEx) and Operating 
Expenditure (OpEx). Where possible, vendor prices were used for process equipment of comparable 
capacity, and capacity-cost correlations were used this data unavailable.33 
The CapEx (2) includes the Battery Limits Installed Cost (BLIC), contingency (Ccont) and working 
capital (CWC): 
   ecinspipinstot CCCCFOBBLIC  11 2  (20)
   i i
ip
ai
bi
aiiTot cfS
S
CnFOB  (21)
BLICfC concon   (22)
matwcwc CfC   (23)
 
Subscripts B and A denote two identical pieces of equipment which are at different scales, or 
capacities, given by SB and SA. These capacities are of a dimension inherent to the equipment: 
examples include tank volume and filter area. The exponent n is particular to a type of equipment, and 
typically ranges between 0.0–1.0. In addition, other factors, summarised above as f can be applied to 
take into account design options such as construction material or design operating conditions. Where 
there is a significant surplus in the applicable capacity range to the required capacity, these additional 
factors were not used. Where the determined price corresponds to the past, the Chemical Engineering 
Plant Cost Index (CEPCI) was used to calculate the inflation to allow appropriate cost adjustments to 
the present time. 
The use of inflation-adjusted equation (21) produces the Free-on-Board (FOB) cost. The Chilton 
Method was then used to estimate the Battery-Limits-Installed-Cost.34 The installed equipment cost 
Cins was taken to be 1.43 times the FOB. Process piping Cpip and instrumentation Cins2were taken to be 
0.3 and 0.12 times the installed equipment costs, respectively; the sum of the installed, piping, and 
instrumentation costs then forms the total physical plant cost, to which a final factor for engineering 
and construction Cec (0.3) is included, producing the BLIC. 
The working capital Cwc is estimated to be 3.5% of annual material costs.1 The contingency Ccon 
was set at 20% of the BLIC. Finally, the total CapEx required is then the sum of the BLIC and the 
WCC. 
The cost of material purchase (Cmat, including reagents, catalysts and solvents) forms a significant 
portion of the OpEx, equation (3); the rest includes utilities (Cutl) and waste disposal (Cwas) costs: 
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The vast majority of waste is solvent and antisolvent, and as such these have been assumed to be 
the entirety of the waste with respect to calculating waste handling costs. 
The material prices have been sourced from vendors as well as official records of imports and 
exports to and from countries including but not limited to France, Spain, Germany, Iran, Saudi 
Arabia, China, Bangladesh and India. 
A subset of the established heuristics employed by Schaber et al.1 have been used to estimate the 
balance of the OpEx, which is utilities and waste disposal costs. Utilities costs have been estimated 
based on the total amount of material input: a figure of £0.96/kg has been used. Waste disposal costs 
have been estimated at £0.35/L for solvents, which constitute a significant majority of the waste. 
3.3 Constraints 
This NLP model is relatively small, and it has been implemented in MATLAB. Separate 
optimisations were performed for temperatures and solvents (25 °C, 45 °C, and 65 °C, and with either 
toluene or n-hexane). The objective was to minimise the total cost, i.e. the NPV, as calculated by 
Equation (18): 
 
100, APIprM  (27)
001.0,32 sTd                      Ts,  (28)
0025.0, sTtV                      Ts,  (29)
00.550.0  sTr                 Ts,  (30)
1fsf  (31)
10  kix  ik,   
i
kix 1   (32)
 
The key constraints were target API production (27), the droplet size of the dispersed phase, d32, 
required for the empirical relations used to be valid (28), a lower bound on key decision variable of 
LLE vessel (mixer tank) volume (29) to ensure it would not regress to insignificantly small values. 
To further keep the problem small and understandable the main decision variable of solvent-to-feed 
ratio (essentially the mass of solvent per mass of incoming raw feed from the effluent of the third 
reactor) was restricted from 0.5 to 5.0 by mass (30); the surrogate equations used were derived from  
data within this range. We have also considered the possibility for flow splits, which implies that we 
would have a number of parallel LLE vessels (31); naturally, this must be unity or above. Finally, 
there were of course constraints on mole fractions (32). 
The constraint on droplet size, equation (28), can potentially result in a region where the objective 
function cannot be computed.35 Foreseeing the potential for algorithms to find local optima as a result 
of this gap, a global search was performed for the optimisation, where convergence was checked from 
multiple local starting points; no other local minima were found in the total cost surface, and NLP 
optimisation results are consistent with our published conceptual ibuprofen CPM separation design.36 
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3.4 Code structure and subroutines 
The MATLAB code has a three-tier structure. At the base tier, the physical, chemical and design 
variables were calculated, encompassing reactor volumes, mass transfer, thermodynamics, and 
product recovery; equations (4–19) are used in this tier, as well as mass transfer and physical 
phenomena constraints. 
The intermediate tier consisted of cost estimation calculations; equations (1, 3, 20–26) are used 
here, as well as API production level constraints. This tier calls the base tier, and estimates costs 
based on the returned variables. Production level constraints are applied at this stage. 
The final, top tier applied the nonlinear optimisation, computing the total cost minimisation. In this 
top tier, some key design space constraints are applied (LLE tank volume Vt, solvent : feed ratio r), 
and calls the intermediate tier. The solver employed, fmincon, used the default trust-region-reflective 
method, with tolerances of 10-6. The local solver fmincon was used as there are a variety of non-
convexities in the design space, as well as non-continuous regions (where functions can’t be evaluated 
due to the applicability range of empirical equations). To make the problem less computationally 
demanding to solve, fmincon was used from a variety of starting locations, and the final converged 
result checked to see if it was the same for all cases; they were, indicating strong results. Gradients 
were automatically calculated. 
3.5 Evaluation of design space 
To inform the formulation of the optimisation problem and investigate the design space, the behaviour 
of the mass transfer coefficient (K), interfacial area (a) and the stage efficiency (E) with varying mixer 
tank volume (Vt) and solvent-to-feed ratio (r) were investigated. These investigations of the design 
space, while not the primary focus of this work, illustrate how Quality by Design (QbD) principles 
can be employed to maximise process potential using systematic evaluation. 
Results indicate slightly more pronounced surfaces for K and a in the case of toluene (Figure 11, 
Figure 12) in comparison to n-hexane (Figure 13, Figure 14). For both solvents, K is promoted by 
higher rates of solvent use r and tank volume Vt. This is intuitive, as more solvent should among other 
effects lead to greater concentration driving forces. In contrast, while greater tank volumes also 
promote interfacial areas between the two immiscible phases, there are significant non-convexities, 
with a being highest in the region of r = 1 to 1.5 for given tank volumes. It is interesting that we do 
not obtain the highest specific surface area by driving the solvent to feed ratio to bounds, and there are 
local optima at intermediate solvent to feed ratios for which we get the maximisation of specific 
surface area; with respect to tank volume of interfacial area increases monotonically. This is likely 
due to the empirical nature of the relations used here, and the mechanics of droplet formation and 
droplet size for given volume fractions.  
The LLE stage efficiency E used here has been formally defined by Treybal in the mid-1960s. The 
behaviour of E was broadly similar for all cases (Figure 15). It is generally high for the range of tank 
volumes studied, but dropping off significantly with lowest tank volumes and high rates of solvent 
use, tank volumes lower than 2.5 L were not studied due to this sharp drop off. This is also intuitive, 
as in these cases it is simply not feasible for sufficient mass transfer to occur in a tank of such a size 
which would have a small residence time. As long as we do not operate at very low tank volumes 
suitably high stage efficiencies can be assured, and this observation holds true for all four cases. 
There is a faint valley in the design spaces of K, a and E in the case of toluene. A plane of 
approximately r = 0.6 bisects the surfaces. This is the point demarking where phase inversion occurs. 
Here, it has been assumed that the phase (aqueous or organic) with the highest mass is the continuous 
phase, while the other is the discrete phase. Furthermore, it should be noted that while this is indeed 
an estimation: there is no definite way in which the point of phase inversion, the volume fraction at 
which the dispersed and continuous phases switch, can be predicted. It is highly dependent on fluid 
properties, temperature, mixing, and mechanical aspects of the mixer and impeller. Here, it has been 
assumed that the aqueous phase is dispersed, except at the lowest of solvent-to-feed ratios, where it is 
unlikely that the aqueous phase remains dispersed. This is the reason for the faint valley seen in 
Figure 11–Figure 15, at the low end of r. 
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While not as apparent in the results shown here, in previous work there was an interesting 
discontinuity in the surfaces for K, a, and E, arising from the maximum permissible dispersed phase 
droplet size (the Sauter mean diameter, d32).35 This is visible for the surfaces of n-hexane (Figure 13–
Figure 15). Care must always be taken when using empirical relations with defined regions of 
applicability, as they could lead to local optima. 
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T = 25 °C 
 
T = 45 °C 
 
T = 65 °C 
 
Figure 11.  Mass transfer coefficient variation with solvent : feed ratio and LLE tank volume for toluene use. 
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T = 25 °C 
  
T = 45 °C 
 
T = 65 °C 
  
Figure 12. Interfacial area variation with solvent : feed ratio and LLE tank volume for toluene use. 
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T = 25 °C 
   
T = 45 °C 
  
T = 65 °C 
  
Figure 13. Mass transfer coefficient variation with solvent : feed ratio and LLE tank volume for n-hexane use. 
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T = 25 °C 
  
T = 45 °C 
  
T = 65 °C 
  
Figure 14. Interfacial area variation with solvent : feed ratio and LLE tank volume for n-hexane use. 
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T = 25 °C 
Toluene n-Hexane 
  
T = 45 °C 
Toluene n-Hexane 
  
T = 65 °C 
Toluene n-Hexane 
  
Figure 15. Variation of stage efficiency E with tank volume, solvent-to-feed ratio, and temperature. 
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4 RESULTS AND DISCUSSION 
Solution time for each formulation (two solvent cases, each at two temperatures) was generally fast, in 
the order of 1~10 seconds, due to the concise nature of the formulations. The optimal cost for toluene 
is 761.4x103 GBP, and corresponds to a solvent-to-feed ratio of 0.5, a mixer tank of 4.66 L volume, 
operating at 65 °C. For n-hexane, the optimal cost is slightly lower at 728.5x103 GBP, also for a 
solvent-to-feed ratio of 0.5, for a mixer tank of 5.70 L, and also operating at 65 °C. This would also 
beneficial with respect to cooling – there would be no reason to cool the reactor effluent to ambient 
temperature Detailed views of the optima for each formulation are given in Figure 16 (toluene) and 
Figure 17 (n-hexane). 
A useful and versatile metric for quantifying environmental impact, E-factor has multiple 
definitions, the simplest of which is the quantity of waste generated per unit of product, in mass terms. 
Highly efficient industries relying almost completely on continuous production techniques – such as 
oil and gas – have E-factors in the order of 0.1, while batch-reliant processes such as pharmaceutical 
production generate significant relative amounts of waste with high E-factors of 200 not uncommon.37 
In this paper, the E-factor is computed where the product is (pure) recovered API, while the waste 
consists of byproducts (bpd), unconverted reactants (ur), waste solvent (ws, all assumed unrecovered), 
and unrecovered API (uAPI): 
 
API
uAPIwsurbpd
API
was
m
mmmm
m
m
factorE
-  (33)
 
There is a consistent trend of lower cost and better (lower) E-factors with increasing temperature 
for both solvents (Figure 18). For each temperature, n-hexane outperforms toluene. Regarding the 
total cost surfaces for each case, despite the non-convexities with respect to the design space, there is 
a much more benign profile (compared to the surfaces of K, a and E) for both toluene and n-hexane at 
all temperatures. The solvent to feed mass ratio is driven to bounds for toluene; indeed, lower rates of 
solvent use become unrealistic, requiring significant residence times. We also see that at the higher 
temperature we obtain both a lower tank volume as well as a lower total cost computed from the 
model (Figure 16, Figure 17). This makes sense: with the more preferable product API distribution at 
higher temperatures (Figure 7, Figure 8), a smaller tank is required for the desired performance. 
By far the biggest determinant of total cost is the solvent-to-feed ratio (r). In Figure 16 and Figure 
17, the axes for r have been restricted to better display the surface trends around the optima; this 
enhanced resolution also has the effect of making the region where the empirical correlations are 
inapplicable appear wider than they are (Figure 17). Were the axes not restricted, the effect of r is 
such that the optima are not clearly visible. There is a large effect from r due to the variation in 
theoretically possible API product recovery, which is calculated from UNIFAC estimates of its 
solubility in each phase (Figure 7, Figure 8). At higher values of r, maximum recovery drops, leading 
to a large increase in process throughput and reactor dimensions if the constraint of 100 kg/year API 
production is to be satisfied; this is the reason r is pushed to the lower bound of 0.5. Given the low 
quantities of solvent used in this extraction stage relative to the feed, long residence times will likely 
be required to ensure adequate inter-phase contact and mass transfer. 
There is a trade-off between tank size and rate of inter-phase API mass transfer in the mixer unit. 
Mass transfer coefficients and interfacial areas both improve with greater mixer tank volume. This 
effect is even more pronounced in the case of stage efficiency (the amount of API recoverable by the 
given design of the tank), with it exponentially decreasing with lower tank volumes (Figure 6). This 
exponential decrease also drastically increases costs, again due to the higher throughput required to 
meet 100 kg/year of API production. 
The ideal number of mixer tanks was always one – it was pushed to bounds. Although this does not 
of course quantify the added redundancy and flexibility provided by having additional tank, for 
normal operation, one mixer tank always resulted in the lowest total cost. 
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While we compute E-factors and use them to evaluate the potential ‘greenness’ of the processes, it 
was not used as an explicit constraint in the optimisation problem. Firstly, in these cases E-factor  
T = 25°C 
  
T = 45°C 
  
T = 65°C 
  
Figure 16. Optima for the use of toluene. 
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performance is already much better with respect to batch manufacturing. The reason that E-factors 
were not included as explicit constraint was from running the risk of infeasibility due complicated  
T = 25°C 
  
T = 45°C 
  
T = 65°C 
  
Figure 17. Optima for the use of n-hexane. 
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thermodynamics and solubilities, even with taking into account the assumptions and simplifications 
that were made. Although it would indeed be possible to re-cast the problem in a multi-objective 
framework, with E-factors as a constraint, it is unlikely that feasibility could be ensured while 
environmental constraints posing strict limits. In such a case a much broader search space would be 
required, where for example mixed-integer components may be needed for the sake of solving over a 
much wider set of solvents and an entire spectrum of temperatures. While exhaustive, this would be 
computationally demanding at this stage. 
There is an interesting tradeoff to be made with respect to which case to use. It can be seen that 
while toluene cost slightly more than n-hexane, and generates more waste (poorer E-factor). While n-
hexane would be preferred based on these variables, consideration of other metrics qualify its 
preferability, and indeed toluene subsequently emerges as the preferred option given that the cost and 
E-factor differences are small (at 65 °C), and as it is less hazardous compared to n-hexane,36,37 
highlighting how there may be difficult design decisions that are not easily formulated into an 
optimisation problem. 
Summarising, a lowest total cost (728.5×103 GBP) is achieved for the case of n-hexane use at 65 °C 
(Figure 18). The best total cost for toluene, while higher, is only marginally more so at 761.4×103 
GBP, also at 65 °C. With respect to the E-factor, which qualifies how ‘green’ the CPM design is, the 
design cases are comparable apart from toluene a 25 °C, which has a poor E-factor. The best E-factor 
(39.9) is for the n-hexane at 65 °C, again however the best E-factor for toluene is close at 42.1, also 
for 65 °C. Given that the differences are small, the use of toluene at 65 °C is the preferable option, 
considering that it is also more benign than n-hexane. While this value of 42.1 is higher than 
previously computed cases,25 the present work employs more accurate thermodynamics and explicit 
product separation calculations, which results in more conservative but reliable values. 
5 CONCLUSIONS 
We have formulated and solved a nonlinear programming model for optimisation, as total cost 
minimisation, of the final separation stage of an upstream continuous flow production process for 
ibuprofen. The chemistry relies on a continuous synthesis which has been published by Bogdan et al.6 
in 2009. 
Figure 18. Optimal total costs and E-factors for the six design cases. 
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The design space has been mapped by means of mass transfer correlations which probe liquid-
liquid extraction in detail. The most important of the two design variables which we have considered 
is the solvent to feed ratio, which is the greatest contributor to cost and which has been driven to the 
lower bound due to the importance of obtaining higher process efficiencies. 
High API recoveries are promoted by lower solvent ratios, and the optimal operating temperature is 
65 °C for both solvents, where a lowest total cost – 728.5×103 GBP – is achieved for the case of n-
hexane use, and the lowest total cost for toluene is only marginally higher at 761.4×103 GBP. Both 
solvent options attain respectable E-factor values (39.9 for n-hexane, 42.1 for toluene), and given that 
the differences are small, the use of toluene at 65 °C is the preferable option, considering that it is also 
more benign than n-hexane. 
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7 NOMENCLATURE AND ACRONYMS 
A′sT  Coefficient used in equation (6) 
AipsT  Coefficient used in equation (5)  
API  Active Pharmaceutical Ingredient 
asT  LLE tank specific interfacial surface area using antisolvent s at temperature T, m2 m-3 
B′sT  Coefficient used in equation (6) 
BipsT  Coefficient used in equation (5) 
BLIC  Battery-Limits-Installed-Cost of all equipment in a process, part of CapEx, £ 
C*sTd Equilibrium API concentration of the dispersed phase in the LLE tank 
Cai  Reference cost of item a, £ 
CapEx  Capital expenditure, £ 
Ccon  Cost of contingency, £  
Cec  Factor to account for equipment engineering and construction 
cfi Product of factors that take into account specifics (e.g. material of construction) of 
item i, 
Ci  Concentration of species i, mol L-1 
Cins  Factor to account for equipment installation 
Cins2  Factor to account for equipment instrumentation 
CipsT  Coefficient used in equation (5) 
Cmat  Cost of material raw material purchase (including solvents and catalysts), £ 
Cmi0  Initial concentration of species i in PFR m, mol L-1 
Cpip  Factor to account for equipment piping 
CPM  Continuous Pharmaceutical Manufacturing 
Cpurc,j  Cost of purchase of material j, £ kg-1 
CsTd Operating API concentration of the dispersed phase in the LLE tank (also that of the 
product stream) 
Cutl  Cost of utilities, £ 
Cwas  Cost of waste handling, £ 
Cwc  Cost of working capital, £ 
d32  Sauter mean droplet diameter, m 
DAPI,c  Diffusivity of API in the LLE tank continuous phase, m2 s-1 
DAPI,d  Diffusivity of API in the LLE tank dispersed phase, m2 s-1 
di  LLE tank impeller diameter, m 
dt  LLE tank internal diameter, m 
E-factor Environmental factor, a measure of material efficiency, kg (waste)/kg (product API) 
Eo  Eotvos number 
EsT  LLE tank stage efficiency when using antisolvent s at temperature T 
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fcon  Factor relating the contingency to the Battery-Limits-Installed-Cost 
FOB(Tot) (Total) Free-on-Board cost of equipment 
Frc  Froude number (LLE tank continuous phase) 
fsf  Flow split factor (number of parallel separation processes) 
ḟsT  Rate of API recovery, mol s-1 
futl  Factor relating the cost of utilities to the total annual requirements (kg) of material 
fwas  Factor relating the cost of waste handling to the volume of waste 
fwc  Factor relating the working capital to the cost of materials 
kb  Boltzmann constant 
kc  LLE tank continuous phase mass transfer coefficient, m s-1 
kd  LLE tank dispersed phase mass transfer coefficient, m s-1 
ki  Rate constant of species i, L mol-1 hr-1 
KsT  LLE tank overall mass transfer coefficient using antisolvent s at temperature T, m s-1 
mAPI  Mass of API produced after separation, kg yr-1 
mbpd  Mass of by-product waste, kg yr-1 
Ṁpr,API  Annual production of API (kg y-1) 
muAPI  Mass of unrecovered API, kg yr-1 
mur  Mass of unreacted reagent waste, kg yr-1 
mwas  Total mass of waste, kg yr-1 
mws  Mass of solvent waste, kg yr-1 
Ni  LLE tank impeller rotation speed, rps 
NPV  Net Present Value, the total costs over a certain plant lifetime, adjusted to the present 
O  Indicates organic phase 
OpEx  Operating expenditure, £ 
pi  Dimensionless exponent used in cost-capacity equation (21) 
sQ   Volumetric flow through the LLE tank, m
3 s-1 
mQ
   Volumetric flowrate in PFR m, mL hr-1 
r  LLE tank antisolvent : feed ratio (kg kg-1) 
rAPI  Molecular radius of ibuprofen, m 
Rei  Impeller Reynolds number 
Reqj  Annual requirements of material j, kg y-1 
ri  Reaction rate of molecule i, mol L-1 hr-1 
Rmax,sT  Theoretical maximum API recovery using antisolvent s at temperature T 
Sai  Reference capacity of item i, units depend on item type 
Sbi Design capacity of item i, units depend on item type 
Scc/d Schmidt number, continuous (c) or dispersed (d) phase 
Shc/d Sherwood number, continuous (c) or dispersed (d) phase 
T Temperature, °C or K 
VPFRm  Volume of plug flor reactor m, mL 
VtsT  LLE tank volume using antisolvent s at temperature T, m3 
W  Indicates aqueous phase 
We  Weber number 
xipsT  Mole fraction of i in ternary mixture phase p using antisolvent s at temperature T 
xki  Mole fraction of species i in stream k 
Xmi  Conversion of species i in PFR m 
Xmif  Final conversion of species i in PFR m 
y  Discount rate, the correction factor for adjusting costs to the present 
wasv   Annual generation of waste (L y-1) 
μc  LLE tank continuous phase viscosity, Pa s 
μm  LLE tank mixture viscosity, Pa s 
ρc  LLE tank continuous phase density, kg m-3 
ρd  LLE tank dispersed phase density, kg m-3 
ρm  LLE tank mixture density, kg m-3 
σ  LLE tank dispersed phase surface tension, N m-1 
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τ  Plant lifetime, years 
φ  LLE tank dispersed phase volume fraction 
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